BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30639533)

  • 21. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
    Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
    Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
    He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
    PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
    Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
    J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
    Vagiannis D; Yu Z; Novotna E; Morell A; Hofman J
    Biochem Pharmacol; 2020 Aug; 178():114061. PubMed ID: 32497550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells.
    Liu DL; Li YJ; Yao N; Xu J; Chen ZS; Yiu A; Zhang CX; Ye WC; Zhang DM
    Eur J Pharmacol; 2014 Jun; 733():34-44. PubMed ID: 24704556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.
    Wang F; Chen Y; Huang L; Liu T; Huang Y; Zhao J; Wang X; Yang K; Ma S; Huang L; To KK; Gu Y; Fu L
    Oncotarget; 2015 Dec; 6(38):40850-65. PubMed ID: 26506420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
    Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW
    Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an
    Ji N; Yang Y; Cai CY; Wang JQ; Lei ZN; Wu ZX; Cui Q; Yang DH; Chen ZS; Kong D
    Front Oncol; 2019; 9():514. PubMed ID: 31275850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
    Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
    Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
    Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
    Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.